MP1032 / MetrioPharm - LARVOL DELTA

MP1032: Pioneering a Steroid-Sparing Paradigm in Duchenne Muscular Dystrophy Treatment (New Directions 2024) - No abstract available

Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy

Non-steroidal drug MP1032 outperforms steroids in enhancing muscle strength and reducing inflammation in the DMD mdx mouse model. (MDA 2024) - "Objectives: To compare the effects of MP1032, prednisolone and deflazacort on inflammation and muscle strength in the mdx mouse model. MP1032 holds potential to substantially reduce steroid doses in the management of DMD while maintaining or even improving therapeutic outcomes. Also, this could substantially mitigate the detrimental steroid-associated side effects in DMD patients."

Late-breaking abstract • Preclinical • Duchenne Muscular Dystrophy • Genetic Disorders • Inflammation • Muscular Dystrophy • IL6 • TNFA

Efficacy of MP1032 in hospitalised patients with COVID-19. (PubMed, Lancet Reg Health Eur) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Efficacy of MP1032 in hospitalised patients with COVID-19- authors' reply. (PubMed, Lancet Reg Health Eur) - No abstract available

Journal • Infectious Disease • Novel Coronavirus Disease

Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trial. (PubMed, Lancet Reg Health Eur) - "Despite the study's limitation in size and the variation in concurrent SoCs, these findings warrant further investigation of MP1032 as a host-directed anti-viral drug candidate. The study was funded by the COVID-19 Horizon Europe work programme and MetrioPharm AG."

Journal • P2a data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire) - "MetrioPharm AG...announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for MP1032 for the treatment of Duchenne muscular dystrophy....'The Orphan Drug Designation for MP1032 in DMD by the FDA is a very important achievement; it takes us one crucial step closer to obtaining an accelerated market approval of our lead compound for Duchenne patients. MetrioPharm plans to initiate a Phase II clinical trial in DMD in 2024.'"

New P2 trial • Orphan drug • Duchenne Muscular Dystrophy • Immunology

MP1032-CT05: MP1032 Treatment in Patients With Moderate to Severe COVID-19 (clinicaltrials.gov) - P2a | N=132 | Completed | Sponsor: MetrioPharm AG | Recruiting ➔ Completed | Trial completion date: Apr 2022 ➔ Sep 2022 | Trial primary completion date: Apr 2022 ➔ Jul 2022

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

MP1032-CT05: MP1032 Treatment in Patients With Moderate to Severe COVID-19 (clinicaltrials.gov) - P2a | N=120 | Recruiting | Sponsor: MetrioPharm AG | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

MetrioPharm AG Obtains Patent Protection for its Lead Compound MP1032 in Brazil (MetrioPharm Press Release) - "MetrioPharm AG...announces that a further substance patent has been obtained for its lead compound MP1032. The Brazilian patent BR 112012021857-3 was granted on June 22, 2021."

Patent • Immunology • Novel Coronavirus Disease • Psoriasis • Rheumatoid Arthritis

MP1032 Treatment in Patients with Moderate to Severe COVID-19 (clinicaltrialsregister.eu) - P2; N=120; Ongoing; Sponsor: MetrioPharm AG

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP • IFNG • IL6 • TNFA

MP1032 Treatment in Patients With Moderate to Severe COVID-19 (clinicaltrials.gov) - P2a; N=120; Not yet recruiting; Sponsor: MetrioPharm AG

Clinical • New P2a trial • Infectious Disease • Novel Coronavirus Disease • PCR

Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. (PubMed, Int J Mol Sci) - "Preclinical efficacy was elucidated in LPS-induced endotoxemia, a model with heightened innate immune responses that shares many similarities to COVID-19. So far, during oral clinical development with three-month daily administrations, no serious adverse drug reactions occurred, highlighting the outstanding safety profile of MP1032."

Journal • Preclinical • Acute Respiratory Distress Syndrome • Immune Modulation • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Novel Coronavirus Disease • Respiratory Diseases • Systemic Inflammatory Response Syndrome • PARP1

MetrioPharm AG phase II data in psoriasis show dose-response, disease modifying activity and outstanding safety profile (MetrioPharm Press Release) - P2, N=153; NCT03706209; Sponsor: MetrioPharm AG; "MetrioPharm AG...reports positive results from its recently completed Phase II dose finding study of MP1032 in psoriasis patients....The overall response rate (defined as PASI 50 and 75) more than doubled over placebo with even a 4-fold increase in PASI 75 responders....High dose MP1032 showed a statistically significant reduction in all-cause AEs over placebo thereby confirming the expected benign safety profile."

P2 data

Last patient last visit in MetrioPharm’s phase II clinical trial in psoriasis (MetrioPharm Press Release) - "MetrioPharm AG, a pharmaceutical development company, announces that the last patient was now examined during the currently ongoing clinical psoriasis Phase II study (Last Patient Last Visit)....The team at MetrioPharm is now awaiting the validation of the data. Afterwards we will immediately start the data analysis. We are expecting the study’s final results within the next few months."

P2 data • Trial completion

Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis (clinicaltrials.gov) - P2; N=153; Completed; Sponsor: MetrioPharm AG; Recruiting ➔ Completed; Trial primary completion date: Mar 2019 ➔ Jun 2019

Clinical • Trial completion • Trial primary completion date

MP1032: Patent expiry in 2031 (MetrioPharm) - Annual Report 2018

Patent

EQS-News: MetrioPharm AG: MetrioPharm AG publishes annual report for 2018 (Business Insider) - "In the past fiscal year, we were able to decisively advance the development of our lead compound MP1032. Phase II clinical trial successfully initiated...for the indication psoriasis started. Patient recruitment has now been completed to our satisfaction."

Trial status

EQS-news: MetrioPharm AG: MetrioPharm enrolls last patient in phase II study on MP1032 in psoriasis (Business Insider) - "MetrioPharm AG...announces that it has enrolled the last patient with moderate-to-severe plaque psoriasis (PASI entry score 10-20) in its ongoing Phase II clinical trial (Last-Patient-In)....We will then be able to begin validating and evaluating all data. We expect the results of the study in the course of 2019."

Enrollment closed • P2 data